Strong On High Relative Volume: OpGen (OPGN)
Trade-Ideas LLC identified
(
) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified OpGen as such a stock due to the following factors:
- OPGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $9.0 million.
- OPGN has traded 383,251 shares today.
- OPGN is trading at 130.87 times the normal volume for the stock at this time of day.
- OPGN is trading at a new high 13.67% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in OPGN with the Ticky from Trade-Ideas. See the FREE profile for OPGN NOW at Trade-Ideas
More details on OPGN:
OpGen, Inc. engages in developing and deploying precision medicine tools to combat infectious disease in global healthcare settings. OPGN has a PE ratio of 1. Currently there is 1 analyst that rates OpGen a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for OpGen has been 369,100 shares per day over the past 30 days. OpGen has a market cap of $46.6 million and is part of the health care sector and health services industry. Shares are up 57.9% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates OpGen as a
. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow.
Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 73.6% when compared to the same quarter one year ago, falling from -$2.60 million to -$4.51 million.
- Net operating cash flow has significantly decreased to -$3.80 million or 121.08% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- The current debt-to-equity ratio, 0.47, is low and is below the industry average, implying that there has been successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.98 is somewhat weak and could be cause for future problems.
- Compared to other companies in the Biotechnology industry and the overall market, OPGEN INC's return on equity significantly trails that of both the industry average and the S&P 500.
- OPGN's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 65.85%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter.
- You can view the full OpGen Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.